Sukhani told CNBC-TV18, "BHEL has just hit a resistance and we saw a big move last week on the last trading day. But I think that is it and that is done away with. There was some news and it is touching a level it will find difficult to cross. So for me this is a sell into strength stock, sell on rallies. BHEL charts are not at all attractive now. It needs to do a lot of work before we can say the trend is up. The trend here is down."
The company's trailing 12-month (TTM) EPS was at Rs 125.82 per share. (Dec, 2011). The stock's price-to-earnings (P/E) ratio was 2.12. The latest book value of the company is Rs 82.34 per share. At current value, the price-to-book value of the company was 3.23. The dividend yield of the company was 2.34%.
Subscribe to:
Post Comments (Atom)
-
Lupin’s Q2FY17 revenues were in-line with our estimates. Revenues grew by 32% YoY to INR 42.1 bn (as compared to our estimate of INR 41.9 b...
-
Volume grew by 4.2% QoQ, best in last 12 quarters. The company expects strong volume momentum to continue despite the mixed view on clie...
-
Sukhani told CNBC-TV18, “I would still buy Ranbaxy Labs. It was in my buy list in the morning and this tells viewers that we go wrong all th...
No comments:
Post a Comment